This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Serra, V. Articles by Baselga, J. Search for Related Content PubMed PubMed Citation Articles by Serra, V. Articles by Baselga, J.

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

¹ Laboratory of Oncology Research, Medical Oncology Service, and ² Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain; and ³ Novartis Institutes for BioMedical Research-Novartis Oncology, Basel, Switzerland

Requests for reprints: José Baselga, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119, 08035 Barcelona, Spain. Phone: 34-9327-46085; Fax: 34-9327-46059; E-mail: jbaselga{at}vhebron.net.

Key Words: PI3K/mTOR inhibitor • surrogate markers

Phosphatidylinositol-3-kinase (PI3K) pathway deregulation is a common event in human cancer, either through inactivation of the tumor suppressor phosphatase and tensin homologue deleted from chromosome 10 or activating mutations of p110-. These hotspot mutations result in oncogenic activity of the enzyme and contribute to therapeutic resistance to the anti-HER2 antibody trastuzumab. The PI3K pathway is, therefore, an attractive target for cancer therapy. We have studied NVP-BEZ235, a dual inhibitor of the PI3K and the downstream mammalian target of rapamycin (mTOR). NVP-BEZ235 inhibited the activation of the downstream effectors Akt, S6 ribosomal protein, and 4EBP1 in breast cancer cells. The antiproliferative activity of NVP-BEZ235 was superior to the allosteric selective mTOR complex inhibitor everolimus in a panel of 21 cancer cell lines of different origin and mutation status. The described Akt activation due to mTOR inhibition was prevented by higher doses of NVP-BEZ235. NVP-BEZ235 reversed the hyperactivation of the PI3K/mTOR pathway caused by the oncogenic mutations of p110-, E545K, and H1047R, and inhibited the proliferation of HER2-amplified BT474 cells exogenously expressing these mutations that render them resistant to trastuzumab. In trastuzumab-resistant BT474 H1047R breast cancer xenografts, NVP-BEZ235 inhibited PI3K signaling and had potent antitumor activity. In treated animals, there was complete inhibition of PI3K signaling in the skin at pharmacologically active doses, suggesting that skin may serve as surrogate tissue for pharmacodynamic studies. In summary, NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-. [Cancer Res 2008;68(19):8022–30]

This article has been cited by other articles:

				A. C. Faber, D. Li, Y. Song, M.-C. Liang, B. Y. Yeap, R. T. Bronson, E. Lifshits, Z. Chen, S.-M. Maira, C. Garcia-Echeverria, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition PNAS, November 17, 2009; 106(46): 19503 - 19508. [Abstract] [Full Text] [PDF]

				G. Konstantinidou, E. A. Bey, A. Rabellino, K. Schuster, M. S. Maira, A. F. Gazdar, A. Amici, D. A. Boothman, and P. P. Scaglioni Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non-Small Cell Lung Cancer Harboring K-RAS Mutations Cancer Res., October 1, 2009; 69(19): 7644 - 7652. [Abstract] [Full Text] [PDF]

				M. Acosta-Martinez, J. Luo, C. Elias, A. Wolfe, and J. E. Levine Male-Biased Effects of Gonadotropin-Releasing Hormone Neuron-Specific Deletion of the Phosphoinositide 3-Kinase Regulatory Subunit p85{alpha} on the Reproductive Axis Endocrinology, September 1, 2009; 150(9): 4203 - 4212. [Abstract] [Full Text] [PDF]

				B. Markman, F. Atzori, J. Perez-Garcia, J. Tabernero, and J. Baselga Status of PI3K inhibition and biomarker development in cancer therapeutics Ann. Onc., August 27, 2009; (2009) mdp347v1. [Abstract] [Full Text] [PDF]

				S. Di Cosimo and J. Baselga Phosphoinositide 3-Kinase Mutations in Breast Cancer: A "Good" Activating Mutation? Clin. Cancer Res., August 15, 2009; 15(16): 5017 - 5019. [Abstract] [Full Text] [PDF]

				S. Ocak, M. L. Sos, R. K. Thomas, and P. P. Massion High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications Eur. Respir. J., August 1, 2009; 34(2): 489 - 506. [Abstract] [Full Text] [PDF]

				D. W. McMillin, M. Ooi, J. Delmore, J. Negri, P. Hayden, N. Mitsiades, J. Jakubikova, S.-M. Maira, C. Garcia-Echeverria, R. Schlossman, et al. Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Cancer Res., July 15, 2009; 69(14): 5835 - 5842. [Abstract] [Full Text] [PDF]

				F. I. Raynaud, S. A. Eccles, S. Patel, S. Alix, G. Box, I. Chuckowree, A. Folkes, S. Gowan, A. De Haven Brandon, F. Di Stefano, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 Mol. Cancer Ther., July 1, 2009; 8(7): 1725 - 1738. [Abstract] [Full Text] [PDF]

				D. A. Guertin and D. M. Sabatini The Pharmacology of mTOR Inhibition Sci. Signal., April 21, 2009; 2(67): pe24 - pe24. [Abstract] [Full Text] [PDF]

				M. Breuleux, M. Klopfenstein, C. Stephan, C. A. Doughty, L. Barys, S.-M. Maira, D. Kwiatkowski, and H. A. Lane Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition Mol. Cancer Ther., April 1, 2009; 8(4): 742 - 753. [Abstract] [Full Text] [PDF]